Charité Universitätsmedizin Berlin – Campus Benjamin Franklin
- Address
- Hindenburgdamm 30, 12200 Berlin, Germany
Charité Universitätsmedizin Berlin – Campus Benjamin Franklin
Charité Universitätsmedizin Berlin – Campus Benjamin Franklin is a distinguished academic medical center with specialized expertise in infectious diseases and critical care medicine. The institution maintains a strong focus on advancing treatment strategies for life-threatening fungal infections, particularly those affecting immunocompromised patients.
- Invasive fungal disease management and novel antifungal therapies
- Treatment optimization for invasive aspergillosis in high-risk populations
- Comparative effectiveness research in antimicrobial therapy
The center actively participates in international clinical trials evaluating next-generation antifungal agents for challenging invasive Aspergillus infections. Their research contributes to establishing new therapeutic standards for patients with invasive fungal diseases, particularly those with lower respiratory tract involvement and systemic infections requiring intensive medical management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 14TEEN4 Pharmaceuticals GmbH1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Charité Universitätsmedizin Berlin – Campus Benjamin Franklin
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Evaluation of Safety, Tolerability, and Efficacy of AL002 and Florquinitau (18F) in Patients with Alzheimer's Disease | Alector LLC | Phase II | Not Recruiting | Apr 2023 | Nov 2024 |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amphotericine B, Liposome | 1 | Unknown | 2022-02-15 | 2022-02-15 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.